CGA(SH:600297)2014-10-22 16:00Financial Performance - Operating income decreased by 25.84% to CNY 229,768,923.05 for the period from January to September[8] - Net profit attributable to shareholders decreased by 10.06% to CNY 27,093,845.08 for the same period[8] - Basic and diluted earnings per share decreased by 10.06% to CNY 0.07741[9] - The company reported a net profit of CNY 18,600,035.54 after deducting non-recurring gains and losses, a decrease of 16.77%[8] - Total operating revenue for Q3 2014 was ¥66,438,098.37, a decrease of 31.4% compared to ¥96,825,909.68 in Q3 2013[34] - The net profit attributable to the parent company for Q3 2014 was CNY 11,306,082.54, down 21.5% from CNY 14,391,565.10 in Q3 2013[36] - The total profit for Q3 2014 was CNY 12,168,089.89, a decline of 25.5% from CNY 16,226,053.90 in Q3 2013[35] - The total operating revenue for Q3 2014 was CNY 20,881,004.95, a decrease of 14.5% compared to CNY 24,376,535.58 in Q3 2013[38] Cash Flow - Cash flow from operating activities decreased by 50.84% to CNY 27,619,643.03 compared to the same period last year[8] - Operating cash flow decreased by 50.84% from CNY 56,181,860.32 to CNY 27,619,643.03, mainly due to reduced net cash inflow from goods purchase and sales[18] - Cash inflow from investment activities totaled CNY 63,164,604.06, significantly higher than CNY 1,799,000.00 in the previous year[48] - Cash outflow from investment activities reached CNY 218,960,130.51, leading to a net cash flow from investment activities of -CNY 155,795,526.45[48] - Total cash outflow from operating activities was CNY 96,304,633.63, resulting in a net cash flow from operating activities of CNY 90,563,150.60, up from CNY 36,653,798.13 year-on-year[47] - The company reported a significant increase in cash received from operating activities, with CNY 104,675,135.23 received from other operating activities compared to CNY 29,204,063.58 last year[47] Assets and Liabilities - Total assets increased by 9.31% to CNY 1,504,411,532.80 compared to the end of the previous year[8] - Total assets as of September 30, 2014, amounted to ¥1,224,822,559.04, slightly down from ¥1,228,386,844.37 at the beginning of the year[31] - Total liabilities increased to ¥379,043,078.23 from ¥384,058,909.73 at the beginning of the year, indicating a decrease of 1.3%[31] - Cash and cash equivalents decreased significantly to ¥23,927,600.75 from ¥105,392,105.04 at the beginning of the year, a decline of 77.3%[29] - Cash and cash equivalents decreased by 66.50% from CNY 154,025,345.34 at the beginning of the period to CNY 51,594,735.05 at the end, primarily due to cash payments for the acquisition of Noxin Bio equity[14] Shareholder Information - The total number of shareholders reached 35,117 by the end of the reporting period[11] - The largest shareholder, Meiluo Group, holds 48.36% of the shares, with 169,265,014 shares pledged[11] Investments and Acquisitions - The company established a wholly-owned subsidiary in Delaware, USA, with a registered capital of USD 1.5 million, completed during the reporting period[21] - The company is actively promoting a major asset restructuring, with stock trading suspended since September 16, 2014, to avoid abnormal price fluctuations[19] - Investment cash flow significantly decreased from CNY -10,122,498.08 to CNY -148,658,852.32, primarily due to the acquisition of Noxin Bio equity[18] Inventory and Receivables - Accounts receivable decreased by 34.23% from CNY 72,440,592.79 to CNY 47,645,310.43, mainly due to reduced receivables from Guangdong Junyuan[15] - Prepayments decreased significantly by 96.24% from CNY 150,289,658.04 to CNY 5,654,720.99, attributed to the use of real estate in Shenyang as partial consideration for the acquisition of Noxin Bio equity[15] - Other receivables increased by 537.89% from CNY 14,703,606.30 to CNY 93,793,566.09, mainly due to changes in the scope of consolidation[15] - Inventory increased by 44.88% from CNY 42,501,472.02 to CNY 61,577,976.72, primarily due to an increase in products at the Chinese medicine factory[15] Expenses - The company incurred a management expense of CNY 15,650,674.98 in Q3 2014, slightly up from CNY 15,489,422.80 in Q3 2013[35] - The company incurred CNY 15,739,795.11 in dividend payments and interest, compared to CNY 13,712,744.40 in the previous year[48]